Pharmaceuticals, Biotechnology & Life Sciences

iBio insiders buying 38,000 options amid a 34% share drop shows confidence—learn what this signals for investors.

Oruka Therapeutics insider buying by CMO Joana Gonçalves signals confidence in its cardiovascular pipeline and commercial strategy, offering investors insight into future upside.

Wang Xiaodong’s recent buy of Oncolytics Biotech ADS signals hidden upside as Cohort‑5 data looms, offering long‑term investors a discounted entry point.

Insider trades by Nurix executives on 15 Oct 2026 show routine 10b‑5‑1 liquidity moves, not market signals—focus on fundamentals, pipeline, and shareholder alignment.

ADAR1 Capital’s recent buy‑in of InMed Pharma signals confidence in its cannabinoid pipeline and regulatory prospects—could spark a micro‑cap rally for savvy investors.

CEO Martine Rothblatt’s 9,500‑share purchase shows steady confidence in United Therapeutics, with minimal market impact and a positive outlook on prostacyclin growth.

Insider buys signal confidence in Alaunos Therapeutics’ new Velaris cardiopulmonary pipeline and potential upside after the recent acquisition.

Investor alert: Alector’s insider buying and option repricing signal executive confidence in its Alzheimer’s pipeline and potential upside—watch Phase‑2 milestones and payer talks.

Regeneron insider trading: Andrew Murphy’s 17,000‑share buy and 12,853‑share sell reveal a confident, compliant long‑term stance amid a 52‑week high and robust biotech outlook.

CEO Mark Lappe buys 2.5 m Inhibrx shares after an 8.7% drop, showing strong insider confidence in a clinical‑stage drug pipeline poised for a rebound.